Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and outcomes, leading to an expanding use in millions of patients worldwide. However, they can cause a spectrum of immune-related adverse events (irAEs). Essentially, any organs can be affected by irAEs, which have emerged as therapy-limiting side effects. In the kidneys, ICI-associated acute interstitial nephritis (ICI-AIN) leads to acute kidney injury (AKI) in 2%–5% of patients on ICI therapy. AKI associated with ICI therapy pathologically presents with AIN in nearly 90% of the cases, but the pathophysiology of ICI-AIN remains to be defined. The generation of autoreactive T cells in patients receiving AIN-inducible drugs, such as proton pump inhibitors (PPIs), is one of the leading theories, supported by a higher incidence of ICI-AIN in patients on these AIN-inducible drugs. In this review, we will discuss our understanding of the incidence, potential pathophysiological mechanisms, clinical presentations, risk factors, diagnosis, and management of PPI-related AIN and its interaction with ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Currently, four different classes of ICIs have been approved by the US Food and Drug Administration (FDA) for treatment of various cancers [1, 2], including anti-cytotoxic T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and…”
BackgroundPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883 · cited 1×
“…T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and pembrolizumab), or PD-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab), and the most recent one antilym-phocyte activation gene-3 (LAG-3) (relatlimab) [3–6].”
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · cited 1×
“…T lymphocyte–associated protein 4 (CTLA-4) (ipilimumab), anti-programmedcelldeathprotein1(PD-1)(cemiplimab,nivolumab, and pembrolizumab), or PD-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab), and the most recent one antilym-phocyte activation gene-3 (LAG-3) (relatlimab) [3–6].”
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7193 · Cited by 729 · cited 1×
“A prospective epidemiologic study using the Atherosclerosis Risk in Communities database in the USA suggested a 31% increase of the risk for PPI-AIN in patients taking twice-daily dosages of PPIs compared to a single daily dosage [34].”
Method25 Years of Proton Pump Inhibitors: A Comprehensive Review
Strand, D. S., Kim, D., & Peura, D. A. (2017) · Gut and Liver · doi:10.5009/gnl15502 · Cited by 671 · cited 1×
“PPI is mainly used for treatment of acid-related disorders, such as peptic ulcer disease, GERD, erosive esophagitis, and Barrett’s esophagus [29].”
BackgroundClinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Cited by
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Self-citationMohan, A., Krisanapan, P., Tangpanithandee, S., Thongprayoon, C., Kanduri, S. R., Cheungpasitporn, W., & Herrmann, S. M. (2024) · American Journal of Nephrology · doi:10.1159/000538274 · Cited by 28
Self-citationMiao, J., Thongprayoon, C., Krisanapan, P., Buglioni, A., Craici, I. M., & Cheungpasitporn, W. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.026 · Cited by 18
“13-15 In our cohort, AIN related to ICIs has already surpassed that associated with NSAIDs.”
Self-citationStone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
“It is possible that this association may be specific to certain cancer types, as PPIs have also been reported to have a neutral or potentially beneficial effect on patient survival 144–146 .”
Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors
Laurent, L., Abbar, B., Bihan, K., Dumas, É., Jochum, F., Lebrun‐Vignes, B., Spano, J., Salem, J., Hamy, A., Reyal, F., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3721 · Cited by 13
Metadata
- Authors
- Miao, J., & Herrmann, S. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Herrmann, Sandra M
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-15
- Volume
- 16
- Issue
- 11
- Pages
- 1834-1844
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC10616479
- OpenAlex
- W4382790817
- Cited by
- 31
- References
- 106
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 11 · 2023: 3
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Korea National Institute of Health (K08 DK118120)
- NIDDK
- CCaTS (UL1TR002377)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- immune checkpoint inhibitors, proton pump inhibitors, acute interstitial nephritis, immune-related adverse events, acute kidney injury, drug-induced nephrotoxicity, autoreactive T cells, pathophysiology, risk factors, diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis. https://app.cochat.ai/papers/10.1093/ckj/sfad109
- The paper
- Miao, J., & Herrmann, S. M. (2023). Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfad109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.